Holen Sie sich die Stockscreener-App
20.30
0.39%
-0.095
Schlusskurs vom Vortag:
$20.40
Offen:
$19.51
24-Stunden-Volumen:
16,102
Relative Volume:
0.06
Marktkapitalisierung:
$326.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.92%
1M Leistung:
+31.01%
6M Leistung:
-13.57%
1J Leistung:
-51.61%
1-Tages-Spanne:
$19.51
$20.62
1-Wochen-Bereich:
$19.13
$22.00
52-Wochen-Spanne:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
20.30 | 326.89M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.85 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.70 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
580.56 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
271.94 | 27.80B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene (NGNE) Price Target Raised by BMO Capital | NGNE Stock News - GuruFocus
Neurogene Approves Amendments at Annual Stockholders Meeting - TipRanks
Neurogene price target raised to $26 from $22 at BMO Capital - Investing.com Canada
Neurogene Inc. (NASDAQ:NGNE) Receives $44.60 Consensus PT from Brokerages - Defense World
Two Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Highlights Gene Therapy Advancements in New Update - TipRanks
Neurogene Inc. (NASDAQ:NGNE) Stock Position Lifted by Wellington Management Group LLP - Defense World
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Squarepoint Ops LLC Has $398,000 Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World
BNP Paribas Financial Markets Cuts Stake in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Reports Q1 2025 Financial Progress and Updates - TipRanks
Northern Trust Corp Buys 5,845 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
BMO Capital Markets Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) Stock - Defense World
Deutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene (NGNE) Receives Price Target Boost from BMO Capital | - GuruFocus
Neurogene (NGNE) Receives Price Target Boost from BMO Capital | NGNE Stock News - GuruFocus
Neurogene stock target raised to $22 by BMO Capital - Investing.com Nigeria
ASGCT Roundup: Sarepta, Rocket, Neurogene and the World’s First Tailored CRISPR Therapy - NewsBreak: Local News & Alerts
Neurogene introduces gene therapy monitoring system after patient death - Yahoo Finance
Neurogene (NASDAQ:NGNE) Stock Rating Lowered by Robert W. Baird - Defense World
Baird R W Downgrades Neurogene (NASDAQ:NGNE) to Hold - Defense World
Neurogene presents HLH treatment strategy at ASGCT meeting By Investing.com - Investing.com Nigeria
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.20 - Defense World
Neurogene Shares Drop After Downgrade From Baird - marketscreener.com
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
Neurogene stock downgraded at Baird (NGNE:NASDAQ) - Seeking Alpha
Neurogene (NGNE) Downgraded to Neutral with Lowered Price Target | NGNE Stock News - GuruFocus
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy - GuruFocus
Neurogene presents HLH treatment strategy at ASGCT meeting - Investing.com Australia
Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav - marketscreener.com
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy Complication | NGNE Stock News - GuruFocus
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Eagle-Tribune
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 By Investing.com - Investing.com Nigeria
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | NGNE Stock News - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 - Investing.com
Q2 Earnings Estimate for Neurogene Issued By HC Wainwright - Defense World
Rett Syndrome treatment Market Is Booming Worldwide 2025-2032 | - openPR.com
HC Wainwright Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted | - GuruFocus
Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained | N - GuruFocus
Wells Fargo & Company MN Purchases 1,397 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Barclays PLC Has $401,000 Position in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene: Q1 Earnings Snapshot - San Francisco Chronicle
Neurogene Reports Q1 2025 Financial Results and Advances Rett Syndrome Gene Therapy - TipRanks
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):